Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EU Priority Medicines Scheme: Early Eligibility, Regular Advice, And A Bonus For SMEs

This article was originally published in SRA

Executive Summary

The European Medicines Agency has confirmed that its proposed priority medicines initiative, PRIME, will be targeted at those new medicines that fulfil the current criteria for accelerated assessment – ie, those that could benefit patients who have no treatment options or that represent a major therapeutic advantage over existing products.

Advertisement
Advertisement
UsernamePublicRestriction

Register